CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
This article provides a stock forecast and analyst ratings for CytoMed Therapeutics (GDTC). It includes key metrics such as the stock price, market cap, 52-week range, volume, and average volume. The article also touches upon the company's financial performance, analyst price targets, and a brief overview of the business.
CytoMed Therapeutics Ltd (NASDAQ: GDTC), a clinical-stage biotech company, is making strides in developing affordable cancer therapies using patented allogeneic Gamma Delta T Cells. The company is currently conducting clinical trials in Singapore and plans to expand to Malaysia, while strategically focusing its global market efforts on China and India due to favorable policies and market potential. Despite a challenging biotech funding environment, CytoMed is pursuing a "low-cost survival strategy" by leveraging Southeast Asia's lower costs, hospital partnerships, and China's "Directive 818" to generate revenue and collect clinical data.
This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its last close price, market capitalization, income, sales, key financial ratios, and stock performance metrics. It lists various operational and financial indicators, such as ROA, ROE, profit margins, and insider ownership, alongside information on the company's IPO and analyst recommendations. The data presented reflects the company's status as a healthcare biotechnology firm based in Singapore.
This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its latest stock performance, key financial metrics, and insider/institutional ownership data. It highlights the company's volatility and various financial ratios, offering a snapshot of its current market position. The data presented covers market capitalization, profitability, valuation, and trading statistics as of July 2, 2026.
CytoMed Therapeutics chairman, Choo Chee Kong, is increasing his personal stake in the company by acquiring up to 200,000 shares and also invested S$300,000 in CytoMed’s subsidiary, LongevityBank Pte Ltd, through his wholly owned EP Capital Inc. This investment will double EP Capital's interest in LongevityBank and is intended to fund the development of a new research and development laboratory. Separately, TipRanks' AI Analyst, Spark, has rated GDTC as Neutral, citing weak financial performance offset by improving technical momentum.
This article provides a stock forecast and analyst ratings for CytoMed Therapeutics (GDTC). It includes key metrics such as the stock price, market cap, 52-week range, volume, and average volume. The article also touches upon the company's financial performance, analyst price targets, and a brief overview of the business.
CytoMed Therapeutics Ltd (NASDAQ: GDTC), a clinical-stage biotech company, is making strides in developing affordable cancer therapies using patented allogeneic Gamma Delta T Cells. The company is currently conducting clinical trials in Singapore and plans to expand to Malaysia, while strategically focusing its global market efforts on China and India due to favorable policies and market potential. Despite a challenging biotech funding environment, CytoMed is pursuing a "low-cost survival strategy" by leveraging Southeast Asia's lower costs, hospital partnerships, and China's "Directive 818" to generate revenue and collect clinical data.
This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its last close price, market capitalization, income, sales, key financial ratios, and stock performance metrics. It lists various operational and financial indicators, such as ROA, ROE, profit margins, and insider ownership, alongside information on the company's IPO and analyst recommendations. The data presented reflects the company's status as a healthcare biotechnology firm based in Singapore.
This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its latest stock performance, key financial metrics, and insider/institutional ownership data. It highlights the company's volatility and various financial ratios, offering a snapshot of its current market position. The data presented covers market capitalization, profitability, valuation, and trading statistics as of July 2, 2026.
CytoMed Therapeutics chairman, Choo Chee Kong, is increasing his personal stake in the company by acquiring up to 200,000 shares and also invested S$300,000 in CytoMed’s subsidiary, LongevityBank Pte Ltd, through his wholly owned EP Capital Inc. This investment will double EP Capital's interest in LongevityBank and is intended to fund the development of a new research and development laboratory. Separately, TipRanks' AI Analyst, Spark, has rated GDTC as Neutral, citing weak financial performance offset by improving technical momentum.
This article announces the filing of Form 6K by CytoMed Therapeutics Ltd for June 23. It includes disclaimers about the high risks involved in trading financial instruments and cryptocurrencies, emphasizing that data may not be real-time or accurate and that investors should be fully informed of risks before trading.
This article provides details of a Form 6K filing by CytoMed Therapeutics Ltd for June 23. The content is brief, primarily serving as a notification of the filing, and includes general financial market data such as indices, commodities, bonds, and shares, which are not directly related to the filing itself.
This article reports on the filing of Form 6K by CytoMed Therapeutics Ltd for June 23. The content is presented by Investing.com, a financial markets information platform. It serves as a brief announcement for the regulatory filing.
CytoMed Therapeutics' Chairman and Director, Choo Chee Kong, plans to acquire up to 200,000 company shares through private cash transactions, demonstrating increased personal exposure to the stock. Separately, his entity, EP Capital Inc., invested S$300,000 (approximately US$250,000) into subsidiary LongevityBank Pte Ltd, boosting its stake from 6.4% to 12.0%. These funds will establish an R&D laboratory for product innovation and process improvement, complementing LongevityBank's existing cGMP manufacturing facility for cord blood-derived therapeutics.
This article provides a technical analysis of CytoMed Therapeutics Ltd (GDTC), focusing on support, resistance, indicators, and moving averages. It synthesizes various technical indicators like MACD, RSI, and MA to offer a comprehensive outlook. The analysis indicates a "Sell" signal based on current moving averages and other technical indicators for GDTC.
This article provides an analysis of CytoMed Therapeutics Ltd (GDTC) valuation metrics, specifically Price-to-Earnings (P/E), Price-to-Book (P/B), and Fair Value. It explicitly states that relevant data for P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. The page also presents current stock performance and mentions the company's market capitalization.
This article provides an earnings forecast for CytoMed Therapeutics Ltd (GDTC), focusing on future EPS and revenue growth estimates. It notes that relevant data has not yet been disclosed by the company, thus no forecast figures are available. However, analysts forecast a price target of USD 5.00 for GDTC.
This article provides details on the institutional confidence in CytoMed Therapeutics Ltd (GDTC), including its stock performance, market capitalization, and key institutional shareholders. It lists several institutional investors and individual shareholders, along with their shares held and any percentage change. The data indicates that some institutional holdings have changed, such as mDR Limited decreasing its stake and 28 Consultants Ltd increasing theirs.
This article provides a risk assessment for CytoMed Therapeutics Ltd (GDTC), focusing on its volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return-to-Drawdown Ratio, Skewness, Sharpe Ratio, and Liquidity. The data indicates recent high volatility and significant drawdowns for the company's stock performance.
The article provides a revenue breakdown for CytoMed Therapeutics Ltd (GDTC), focusing on its business segments, regional revenue, and profit contribution. It states that relevant data for these categories have not yet been disclosed by the company. The page also includes current stock information for GDTC.
This article provides an overview of CytoMed Therapeutics Ltd's (GDTC) shareholder structure, detailing major shareholders and institutional holdings. It lists the proportion held by key entities like Glorious Finance Limited and mDR Limited, alongside a breakdown by shareholder types such as corporations and individual investors. The report also includes historical institutional shareholding data and recent shareholder activity.
CytoMed Therapeutics director and ten percent owner Choo Chee Kong purchased 112,000 Ordinary Shares in an open-market transaction at $1.1498 per share, totaling $128,778. Following this acquisition, Choo Chee Kong directly owns 430,324 Ordinary Shares. The filing indicates a positive sentiment towards the company, with no reported derivative positions.
This article provides a stock analysis of CytoMed Therapeutics (Nasdaq:GDTC), highlighting its status as a clinical-stage biopharmaceutical company focused on cell-based immunotherapies. It details the company's financial performance, including declining earnings and an undervalued stock price according to one analyst, alongside recent news and identified risks such as small market capitalization and limited cash runway. The piece also covers significant announcements like clinical trial advancements and research collaborations.
CytoMed Therapeutics (NASDAQ: GDTC) shareholders approved all ten proposals at its Annual General Meeting (AGM) held on May 22, 2026, in Singapore. These approvals included adopting financial statements, re-electing directors Dr. Yew Chak Hua and Dr. Toh Keng Kiat, waiving the Singapore Code on Take-overs and Mergers, and ratifying auditors WWC, P.C. and KE Trust PAC. The shareholders also approved directors' fees of US$70,000 for 2026 and authorized the directors to issue ordinary shares.
This article provides a detailed stock price and quote for CytoMed Therapeutics Ltd (GDTC), including its last closing price, financial metrics, and recent news. It highlights various financial data points like market cap, income, sales, and insider ownership, alongside a chronological list of corporate news and clinical progress updates. The company is characterized as a biopharmaceutical firm focused on immune cell and stem cell-based therapies.
CytoMed Therapeutics director Toh Keng Kiat has reported an initial beneficial ownership of 4,000 Ordinary Shares in the company. This disclosure is a routine Form 3 filing with the SEC and signifies an existing holding rather than a new transaction. The shares are directly owned by the director and have no par value per share.
CytoMed Therapeutics Ltd, a clinical-stage biotech company based in Singapore, is making significant strides in developing affordable cancer therapies using allogeneic Gamma Delta T Cells. Through strategic acquisitions and a focus on global expansion, particularly in China and India, the company aims to overcome the limitations of current cell therapies. Despite challenging biotech market conditions, CytoMed is employing a "low-cost survival strategy" by leveraging Southeast Asia's infrastructure and collaborating with hospitals to provide treatments and gather clinical data.
CytoMed Therapeutics Limited is expanding its international presence, starting with a name change for its subsidiary to CytoMed International Pte. Ltd. The company aims to explore global opportunities, particularly in Asia and China, through potential joint ventures and medical tourism initiatives. CytoMed specializes in developing novel cell-based immunotherapies for cancer, utilizing patent-pending donor blood cell-based and iPSC-derived technologies, with manufacturing facilities in Malaysia.
CytoMed Therapeutics Ltd's Chief Corporate Officer, Tan Yoong Ying, has filed an initial statement of beneficial ownership (Form 3) reporting direct ownership of 25,781 Ordinary Shares with no par value. This SEC filing indicates his existing stake without any recent purchase or sales activity. The filing was made public on May 15, 2026, and details his role and address in Singapore.
CytoMed Therapeutics director Choo Chee Kong filed an initial Form 3 detailing his beneficial ownership in the company. The filing reports direct ownership of 318,324 Ordinary Shares and indirect ownership through Glorious Finance Limited (2,075,310 shares) and EP Capital Inc. (194,112 shares). Mr. Choo disclaims beneficial ownership of 1,697,981 shares held by Glorious Finance Limited where he has no economic interest, providing transparency into his equity stake.
CytoMed Therapeutics' CFO, Yvonne Goh, has filed an initial insider ownership report (Form 3) showing she directly holds 25,781 Ordinary Shares in the company. This filing simply reports her existing stake and does not indicate any recent purchases, sales, or option exercises. The Form 3 serves as an initial statement of beneficial ownership for company officers.
CytoMed Therapeutics director Yew Chak Hua has reported an initial ownership of 2,469 ordinary shares on Form 3, establishing his status as a director with a direct stake. This filing indicates current holdings upon becoming a director and does not reflect any recent buying or selling activities. The report also confirms no derivative securities are held by Mr. Hua.
This article reports on a Form 144 SEC filing by CytoMed Therapeutics Ltd (GDTC). The filing indicates a proposed sale of 117,337 ordinary shares with an aggregate market value of $98,093.73, acquired on April 22, 2021, via a share subscription from the issuer. The sale is scheduled for May 13, 2026, on NASDAQ, and is being handled by Bank of Singapore.
The page displays real-time and delayed quotes for CytoMed Therapeutics Ltd (GDTC) on Nasdaq, showing a current price of 0.809 USD with a 3.72% increase. It presents an overview of the company, financial data, and discussion sections, along with a market cap and P/E TTM information. The platform, TradingKey, provides various financial tools and educational resources, emphasizing a "one powerful score" for smarter investment decisions.
CytoMed Therapeutics (GDTC) has renamed its wholly-owned subsidiary, Advance Cancer Centre Pte. Ltd., to CytoMed International Pte. Ltd., effective May 6, 2026. This move signifies a strategic refocusing on expanding its international presence, particularly in Asia and China, through joint ventures and medical tourism initiatives. The company's allogeneic gamma delta T cell technology is attracting interest in China following Directive 818, and the subsidiary currently holds a 19.0% equity interest in a Malaysian clinic.
This article provides current stock price information for CytoMed Therapeutics Limited (GDTC), trading at $0.76 with a 0.00% daily change. It includes key market data such as market cap, daily highs and lows, and trading volume, alongside performance over different periods. The article also describes the company's focus on cell-based immunotherapies for cancer treatment and offers a guide on how to buy GDTC stock on MEXC.
CytoMed Therapeutics Limited has released its audited financial statements for the fiscal year ended December 31, 2025. The report details the company's financial position, performance, changes in equity, and cash flows for both the Group and the Company. Directors confirmed that the financial statements provide a true and fair view in accordance with Singapore Companies Act 1967 and Financial Reporting Standards in Singapore.
CytoMed Therapeutics Limited will hold its Annual General Meeting on May 22, 2026, where shareholders will vote on ten ordinary resolutions. Key proposals include the adoption of 2025 financial statements, re-election of directors, approval of auditors, and a waiver from the Singapore Code on Take-overs and Mergers. Shareholders will also consider authorizing the board to issue new ordinary shares and related instruments, providing the company with flexibility for future financing and M&A activities.
This article provides a financial overview of GDTC (CytoMed Therapeutics Ltd), detailing its revenue breakdown, profitability margins, and a comparison with competitors OSRH and CVKD. GDTC exhibits a 100.00% gross margin but negative operating and net margins, with a -42.43% Return on Equity. The company competes with a market capitalization of $11.69M.
CytoMed Therapeutics (NASDAQ: GDTC) reported a widening net loss of US$3.11 million in 2025, despite increased revenue, primarily due to higher research and development expenses, employee benefits, and public company costs. The company is making significant clinical progress with its allogeneic gamma delta T cell programs, including its ANGELICA CAR-T Phase I trial in Singapore and planned Phase I trial in Malaysia, alongside preclinical research collaboration with MD Anderson Cancer Center. CytoMed also expanded its strategic assets by acquiring a Malaysian cord blood bank to support future cell-based therapies.
This article provides a detailed analysis and price prediction for CytoMed Therapeutics Ltd (GDTC) stock, indicating a "Strong Sell" recommendation based on negative technical signals, bearish moving average trends, and short-selling activity. Although GDTC experienced a slight increase recently, it has shown an overall decline over the past three years. The report suggests October as the month with the highest probability for positive returns based on seasonality, but generally advises caution due to several negative indicators.
This article features an interview with Choo Chee Kong, Chairman of CytoMed Therapeutics Ltd. (NASDAQ: GDTC). Mr. Choo, with over two decades of corporate finance experience, discusses his background and the company's history. The full interview content is gated, requiring a subscription or purchase.
This page provides a comprehensive resource for CytoMed Therapeutics SEC filings, including 10-K, 10-Q, 8-K, and Form 6-K documents. It details key corporate actions, financial updates, and clinical trial milestones. The article also includes a list of recent SEC filings with AI-generated summaries and sentiment analysis for GDTC.
This article features an interview with Choo Chee Kong, Chairman of CytoMed Therapeutics Ltd. (NASDAQ:GDTC). It provides a detailed professional background of Mr. Choo, highlighting his extensive experience in corporate finance and his previous leadership roles in various listed companies. The piece serves as an introduction to Mr. Choo and CytoMed Therapeutics for readers, with the full interview content available to subscribers.
This article provides recent news and event updates for CytoMed Therapeutics (GDTC), focusing on its advancements in cancer immunotherapy. Key events include the company addressing false claims about its research programs, updating shareholders on 2026 therapy developments, and signing an MoU with Universiti Malaya Medical Centre for a Phase I clinical trial in Malaysia. CytoMed's research primarily involves CAR gamma delta T cell therapies and iPSC-derived gamma delta NKT cell therapies, with ongoing clinical trials in Singapore and collaborative studies, such as one with MD Anderson Cancer Center for Acute Myeloid Leukemia.
This article provides a technical analysis of CytoMed Therapeutics Ltd (GDTC), indicating a "Neutral" overall consensus based on aggregated technical signals. While momentum indicators like RSI and MACD currently show a neutral state, various simple moving averages (5-Day, 10-Day, 20-Day, 60-Day, 200-Day, 250-Day) suggest a "Buy" signal given GDTC's current share price of $1.02. The report also highlights key support and resistance levels for future price movements.
This article analyzes the valuation of CytoMed Therapeutics Ltd (GDTC), indicating it is currently "Undervalued" with a fair price between $1.14 and $2.12 compared to its current price of $1.08. While its forward P/S ratio of 30.85 is significantly above the industry average, suggesting unsustainability given its revenue growth, other metrics like P/B ratio and negative FCF yield are also discussed. The analysis uses relative valuation methods and compares GDTC's metrics to historical averages and competitor benchmarks.
This article highlights three penny stocks—CytoMed Therapeutics (GDTC), Tandy Leather Factory (TLF), and Investview (INVU)—that show promising prospects in the current optimistic market climate. While penny stocks carry high risk, these companies are presented with encouraging financials and strategic developments. The analysis details each company's overview, financial health rating, market capitalization, and key operational insights for potential investors.
CytoMed Therapeutics, a Singapore-based biopharmaceutical company, has released a statement to refute "inaccurate and misleading claims" circulating about its research programs, clinical progress, and operations. The company emphasized its commitment to transparency and regulatory compliance, confirming that its lead CAR γδ T cell program is currently undergoing a first-in-human clinical trial at Singapore's National University Hospital. CytoMed reiterated that none of its therapeutic candidates are approved for commercial use and stated its intention to take action against the dissemination of false information.
CytoMed Therapeutics Limited issued a statement refuting recent inaccurate and misleading claims regarding its research programs, clinical progress, and operations. The company reaffirmed its focus on CAR γδ T cell therapies and iPSC-derived γδ NKT cell therapies, noting that its lead CAR γδ T cell program has received regulatory approval for a first-in-human clinical trial currently underway in Singapore. CytoMed emphasized its compliance with regulations and commitment to accurate communication, reserving the right to act against the dissemination of false information.
CytoMed Therapeutics (NASDAQ: GDTC) has issued a statement refuting inaccurate claims about its research, clinical progress, and operations. The company reaffirmed that its lead CAR γδ T cell program has regulatory approval for a first-in-human trial, which is currently underway in Singapore. CytoMed emphasized that other therapies are still in preclinical stages and no product has been approved for commercial use, and that such misleading claims are designed to affect its share price.
CytoMed Therapeutics (NASDAQ: GDTC) provided a 2026 update on its clinical and corporate progress, including ongoing Phase I CAR T trials in Singapore and plans to submit an IND for a multi-site Phase I CTM-GDT trial in Malaysia. The company is exploring non-dilutive funding options and seeks shareholder feedback on a proposal to allow shareholding to grant access to its donor-derived gamma delta T cell therapies. CytoMed projects it has sufficient resources for at least one year of operations and remains focused on developing affordable, donor-derived cell-based immunotherapies for various cancers.
CytoMed Therapeutics provided a new year update for 2026, highlighting its diversification into cord blood-derived Natural Killer cell development through LongevityBank and support from Enterprise Singapore. The company also announced plans to initiate a Phase I clinical trial in Malaysia for its unmodified Gamma Delta T-cells (CTM-GDT) for no-option cancer patients, complementing an ongoing trial in Singapore. In a unique move, CytoMed is seeking shareholder feedback on a proposal that would allow shareholders to access the company's donor-derived allogeneic unmodified gamma delta T cells using their shareholding, subject to medical and regulatory approval.
CytoMed Therapeutics provides an update for 2026, highlighting the diversification of its product pipeline through LongevityBank, focusing on cord blood-derived Natural Killer cells for cancer treatment, and ongoing clinical trials in Singapore and Malaysia. The company is exploring various funding avenues, received support from Enterprise Singapore, and seeks shareholder feedback on a unique scheme allowing access to its gamma delta T cell therapies.
CytoMed Therapeutics Limited (NASDAQ:GDTC) saw its stock surge 9.6% following the announcement of a partnership with Universiti Malaya Medical Centre for a first-in-human Phase I clinical trial in Malaysia. This collaboration will investigate the safety and efficacy of CytoMed's patented allogeneic unmodified Gamma Delta T cells (CTM-GDT) for cancer patients, aiming to provide an affordable cancer immunotherapy option. The company's technology uses specialized T cells from healthy donors, which is touted as a more cost-effective and accessible alternative to traditional autologous immunotherapies.
